Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

Figure 1 Overall survival in 41 metastatic colorectal cancer treated with cetuximab in II and III lines according to median basal level of invariant natural killer T cells (0. 382 cells/microliter). iNKT: Invariant natural killer T.

Figure 2 Overall survival in 41 metastatic colorectal cancer treated with cetuximab in II and III lines according to median basal level of antibody-dependent cell-mediated cytotoxicity activity (71%). ADCC: Antibody-dependent cell-mediated cytotoxicity.

Figure 3 Overall survival in 41 metastatic colorectal cancer patients stratified for both invariant natural killer T and antibody-dependent cell-mediated cytotoxicity activity at basal level, below and above the respective median level. iNKT = 0.382 cells/microliter; ADCC = 71%. iNKT: Invariant natural killer T; ADCC: Antibody-dependent cell-mediated cytotoxicity.

Figure 4 Progression free survival in compound heterozygote patients for single nucleotide polymorphisms rs1801274 in FCGR2A and rs396991 in FCGR3A genes in the 41 metastatic colorectal cancer patients.

Figure 5 Overall survival in 30 metastatic colorectal cancer patients with a blood drawn after 2 mo (A) and in 23 patients with a blood drawn after 4 mo of treatment (B). Analysis was done in 4 groups of patients: The first included patients showing both ADCC activities above the median level [ADCCbas above/II (or III) above, where II means on blood drawn after 2 mo and III after 4 mo], the second group a decrease from a basal above median to a II or III determination below median [ADCCbas above/II (or III) below], the third group patients showing instead an increase from below at basal and above at II or III determination [ADCCbas below/II (or III) above] and the fourth group patients with both ADCC activities below the median level [ADCCbas below/II (or III) below]. ADCC: Antibody-dependent cell-mediated cytotoxicity.